Davies MJ, Tringham JR, Troughton J, Khunti KK Prevention of Type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabet Med. 2004 May;21(5):403-14. Review.
Feig DI, Kang DH, Johnson RJ Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23;359(17):1811-21. doi: 10.1056/NEJMra0800885. Review. Erratum in: N Engl J Med. 2010 Jun 10;362(23):2235.
Forbes JM, Cooper ME Mechanisms of diabetic complications. Physiol Rev. 2013 Jan;93(1):137-88. doi: 10.1152/physrev.00045.2011. Review.
Hovind P, Rossing P, Johnson RJ, Parving HH Serum uric acid as a new player in the development of diabetic nephropathy. J Ren Nutr. 2011 Jan;21(1):124-7. doi: 10.1053/j.jrn.2010.10.024. Review.
Jia G, Aroor AR, Whaley-Connell AT, Sowers JR Fructose and uric acid: is there a role in endothelial function? Curr Hypertens Rep. 2014 Jun;16(6):434. doi: 10.1007/s11906-014-0434-z. Review.
Kolderup A, Svihus B Fructose Metabolism and Relation to Atherosclerosis, Type 2 Diabetes, and Obesity. J Nutr Metab. 2015;2015:823081. doi: 10.1155/2015/823081. Epub 2015 Jun 14. Review.
Mayes PA Intermediary metabolism of fructose. Am J Clin Nutr. 1993 Nov;58(5 Suppl):754S-765S. doi: 10.1093/ajcn/58.5.754S. Review.
O'Keefe JH, Gheewala NM, O'Keefe JO Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol. 2008 Jan 22;51(3):249-55. doi: 10.1016/j.jacc.2007.10.016. Review.
Riegersperger M, Covic A, Goldsmith D Allopurinol, uric acid, and oxidative stress in cardiorenal disease. Int Urol Nephrol. 2011 Jun;43(2):441-9. doi: 10.1007/s11255-011-9929-6. Epub 2011 Mar 10. Review.
Shaw JE, Sicree RA, Zimmet PZ Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 Jan;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007. Epub 2009 Nov 6.
Shields J, Maxwell AP Managing diabetic nephropathy. Clin Med (Lond). 2010 Oct;10(5):500-4. Review.
Singh DK, Winocour P, Farrington K Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol. 2011 Mar;7(3):176-84. doi: 10.1038/nrendo.2010.212. Epub 2010 Dec 14. Review.
Soltani Z, Rasheed K, Kapusta DR, Reisin E Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep. 2013 Jun;15(3):175-81. doi: 10.1007/s11906-013-0344-5. Review.
Tappy L, Lê KA Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010 Jan;90(1):23-46. doi: 10.1152/physrev.00019.2009. Review.
van Dijk C, Berl T Pathogenesis of diabetic nephropathy. Rev Endocr Metab Disord. 2004 Aug;5(3):237-48. Review.
Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 Mar;87(3):293-301. doi: 10.1016/j.diabres.2010.01.026. Epub 2010 Feb 19. Erratum in: Diabetes Res Clin Pract. 2011 May;92(2):301.
The Effect of Acute Fructose Load in Patients With Chronic Kidney Disease and Patients With Type 2 Diabetes Compared to Healthy Subjects
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.